In that case, blood tau biomarkers could serve as a first screening tool for AD pathology (step 1), followed by confirmatory testing with CSF Aβ42/Aβ40 or PET imaging (step 2) only in patients with intermediate risk at the first step. Here, MAPT is linked to Alzheimer disease.